- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07784855
Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer
WVU011625: The Role of Scheduled Intravenous Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer
Patients undergoing concurrent chemoradiotherapy (CCRT) for head and neck squamous cell carcinoma frequently experience treatment-related toxicities including mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. Many of these toxicities may be exacerbated by dehydration and are commonly managed with clinician-directed intravenous (IV) hydration. This study will evaluate whether scheduled IV hydration reduces the incidence and severity of treatment-related toxicities compared with clinician assessment-based hydration. Participants will be randomized 1:1 to scheduled IV hydration or clinician assessment-based IV hydration beginning in Week 3 of concurrent chemoradiotherapy and continuing through one week following completion of chemoradiotherapy.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Nina Moore
- 전화번호: 304-293-2991
- 이메일: nina.moore@hsc.wvu.edu
연구 연락처 백업
- 이름: Ella Betler
- 전화번호: 304-293-4273
- 이메일: eibetler@hsc.wvu.edu
연구 장소
-
-
West Virginia
-
Bridgeport, West Virginia, 미국, 26330
- 아직 모집하지 않음
- WVU Medicine United Hospital Center
-
연락하다:
- Sabrina Rexroad
- 전화번호: 681-342-1000
- 이메일: sabrina.rexroad1@wvumedicine.org
-
Martinsburg, West Virginia, 미국, 25401
- 아직 모집하지 않음
- WVU Medicine Berkeley Medical Center
-
연락하다:
- Valli White
- 전화번호: 304-264-1220
- 이메일: valli.white@wvumedicine.org
-
Morgantown, West Virginia, 미국, 26506
- 모병
- West Virginia University Cancer Institute
-
연락하다:
- Nina Moore
- 전화번호: 304-293-2991
- 이메일: nina.moore@hsc.wvu.edu
-
수석 연구원:
- David Clump, MD, PhD
-
수석 연구원:
- Sidra Najeeb, MD
-
연락하다:
- Ella Betler
- 전화번호: 304-293-4273
- 이메일: eibetler@hsc.wvu.edu
-
Parkersburg, West Virginia, 미국, 26101
- 아직 모집하지 않음
- WVU Medicine Camden Clark Medical Center
-
연락하다:
- Layla Tannaoury
- 전화번호: 304-424-2585
- 이메일: Layla.tannoury@wvumedicine.org,
-
Princeton, West Virginia, 미국, 24740
- 아직 모집하지 않음
- WVU Medicine Princeton Community Hospital
-
연락하다:
- Melissa Boggess
- 전화번호: 304-487-7515
- 이메일: melissa.boggess1@wvumedicine.org
-
Wheeling, West Virginia, 미국, 26003
- 아직 모집하지 않음
- WVU Medicine Wheeling Hospital
-
연락하다:
- Maher Kali
- 전화번호: 304-243-7045
- 이메일: maher.kali@wvumedicine.org
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- ECOG 0-2
- Non-nasopharyngeal squamous cell carcinoma of oral cavity, oropharynx, hypopharynx, larynx primary
- Planned for concurrent chemoradiotherapy (CCRT) with standard-of-care cisplatin-based regimen (IV cisplatin 100mg/m2 once every three weeks for up to three doses or IV cisplatin 40mg/m2 weekly) with concurrent radiotherapy (treatment duration approximately 6-7 weeks, per institutional standards).
- The use of immunotherapy in combination with CCRT is permitted and does not affect eligibility or group assignment.
Exclusion Criteria:
- Nasopharyngeal squamous cell carcinomas, nasal cavity and paranasal sinus squamous cell carcinomas.
- History of congestive heart failure.
- Dependency on enteral nutrition and hydration prior to enrollment.
- Use of diuretics that cannot be safely held during study treatment (participants who are able to temporarily discontinue diuretics during treatment are eligible).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Scheduled IV Hydration
Participants will receive scheduled IV hydration approximately twice per week throughout the treatment period. IV fluids will continue even if chemoradiotherapy infusion is held due to toxicities or cytopenias. |
Normal saline (0.9% sodium chloride) 1L of saline will be administered at each hydration visit. Participants will receive IV fluids on a planned schedule of twice a week, starting in Week 3 of chemoradiation treatment and continuing for one week after treatment is completed. |
|
다른: Clinician Assessment-Based IV Hydration
Participants will receive IV fluids (normal saline) only as clinically indicated and ordered by their treating clinician, per standard of care. IV fluids may continue if chemoradiotherapy infusion is held due to toxicities or cytopenias, at the discretion of the treating clinician. |
IV fluids (normal saline (0.9% sodium chloride)) only as clinically indicated and ordered by their treating clinician, per standard of care. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of at least one Grade ≥3 Treatment-Related Toxicities of Interest
기간: From initiation of concurrent chemoradiotherapy through completion of treatment (approximately 6-7 weeks)
|
Incidence of participants experiencing at least one Grade ≥3 according to National Cancer Institute Common Terminology Criteria for Adverse Events v6.0 (NCI CTCAE) treatment-related toxicity of interest, including mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, or trismus, during concurrent chemoradiotherapy. |
From initiation of concurrent chemoradiotherapy through completion of treatment (approximately 6-7 weeks)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidences of Individual Treatment-Related Toxicities of Interest
기간: From initiation of concurrent chemoradiotherapy through completion of treatment (approximately 6-7 weeks)
|
Incidence of treatment-related mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus of any grade, as assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 6.0. |
From initiation of concurrent chemoradiotherapy through completion of treatment (approximately 6-7 weeks)
|
|
Incidence of Enteric Tube Placement
기간: From initiation of treatment through 6 months after completion of chemoradiotherapy
|
Incidence of participants requiring enteric feeding tube placement during treatment and follow-up. |
From initiation of treatment through 6 months after completion of chemoradiotherapy
|
|
Incidence of Hematologic Toxicities
기간: Weeks 3-6 of concurrent chemoradiotherapy
|
Incidence of leukopenia, anemia, and thrombocytopenia assessed during weeks 3-6 of concurrent chemoradiotherapy treatment as assessed according to NCI CTCAE v6.0. |
Weeks 3-6 of concurrent chemoradiotherapy
|
|
Residual Grade of Toxicities of Interest at 3 Months
기간: 3 months after completion of chemoradiotherapy
|
Residual severity (NCI CTCAE v6.0 Grades 0-5) of mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. |
3 months after completion of chemoradiotherapy
|
|
Residual grade of Toxicities of Interest at 6 Months
기간: 6 months after completion of chemoradiotherapy
|
Residual severity (NCI CTCAE v6.0 Grades 0-5) of mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. |
6 months after completion of chemoradiotherapy
|
|
Complete Recovery of Toxicities of Interest at 3 Months
기간: 3 months after completion of chemoradiotherapy
|
Incidence of participants with complete recovery (NCI CTCAE v6.0 Grade 0) from mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. |
3 months after completion of chemoradiotherapy
|
|
Complete Recovery of Toxicities of Interest at 6 Months
기간: 6 months after completion of chemoradiotherapy
|
Incidence of participants with complete recovery (NCI CTCAE v6.0 Grade 0) from mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. |
6 months after completion of chemoradiotherapy
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Sidra Najeeb, MD, WVU Cancer Center
- 연구 의자: David Clump, MD, PhD, WVU Cancer Center
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- STUDY00000501
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
De-identified individual participant data collected during the study, including demographic information, eligibility criteria, treatment/exposure data, outcome assessments, and relevant follow-up data, will be made available to qualified researchers. Data that could directly identify participants will not be shared.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .